-
Product Insights
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Muscular Dystrophy Pipeline Drugs Market Report Overview Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The report titled ‘Muscular Dystrophy –Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update’, provides an overview of...
-
Report Bundle
58% offTech in Pharma – Report Bundle (7 Reports)
Tech in Pharma Bundle Report Overview Although the pharmaceutical industry had been slow to adopt technological innovations, the onset of COVID-19 has dramatically altered the situation. The latest technologies, Augmented Reality (AR), Big Data, and Artificial Intelligence (AI), among others, will assist pharmaceutical companies in speeding up the research and development process, creating personalized products, and conducting testing in novel ways. Finally, these technologies will improve healthcare effectiveness and efficiency thereby transforming the patient and provider experience. Explore actionable market...
-
Product Insights
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease – Drugs In Development, 2022, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape. Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs...
-
Product Insights
Pancreatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of pancreatitis include upper abdominal pain, nausea, vomiting, tenderness while touching the abdomen, weight loss, and upper abdominal pain. It can be treated using antibiotics and medication. The Pancreatitis pipeline market research report provides comprehensive information on the therapeutics under development for Pancreatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and...
-
Product Insights
Fragile X Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Fragile X syndrome is caused by a change in a gene called FMR1. It occurs both in males and females. The symptoms of Fragile X Syndrome include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech or language delay, and intellectual disability. The Fragile X Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration...
-
Thematic Analysis
Artificial Intelligence (AI) in Drug Discovery Market – Thematic Research
Explore trends and insights from the following data in the ‘Artificial Intelligence (AI) in Drug Discovery Market’ thematic report: Understanding the key trends impacting the theme over the next 12 to 24 months. Comprehensive analysis of drugs discovered using AI and survey data on the adoption of AI in pharma. Detailed value chain breaks down Artificial Intelligence (AI) in the Drug Discovery Market into Target Identification and Validation, Generation of Molecule Leads/De Novo Drug Design, Drug Repurposing, and Response Biomarker...
-
Product Insights
Friedreich Ataxia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Friedreich Ataxia Drugs in Development Report Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Its signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis...
-
Company Insights
Future Unicorns in Healthtech
Based on the GlobalData Machine Learning Model’s proprietary ranking of 10,000 top startups, 120 Healthtech startups have been shortlisted globally, with 50 of them predicted to become future unicorns. The 10k top startups in the Scorecard are spread over 70 countries with the US accounting for half of them, followed by China. Positive sentiments in the news, continued VC investments, increase in hiring clubbed with growing Healthtech mentions in Company Filings indicate that the Healthtech sector has high interest for...